GlobeNewswire
-
Noom to Bundle a New Wearable, Noom Band, Into Its Popular Enterprise Obesity Care Programs at No Additional Cost
16/11/2026 -
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
16/11/2026 -
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026
16/11/2026 -
Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products
16/11/2026 -
Medline Inc. announces launch of secondary offering of Class A common stock
16/11/2026 -
CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
16/11/2026 -
Transactions under Novonesis’ share buyback program
16/11/2026 -
Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations
16/11/2026 -
Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
16/11/2026 -
Zymeworks Announces $200 Million Share Repurchase Authorization
16/11/2026 -
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
16/11/2026 -
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
16/11/2026 -
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
16/11/2026 -
Vivani Medical Announces Private Placement Equity Financing
16/11/2026 -
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
16/11/2026 -
Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease
16/11/2026 -
NTG Nordic Transport Group A/S – Capital Markets Day Agenda
16/11/2026 -
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
16/11/2026 -
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
16/11/2026
Pages